Variability of the IFN-γ ELISpot assay in the context of proficiency testing and bridging studies.

dc.contributor.author

Rountree, Wes

dc.contributor.author

Berrong, Mark

dc.contributor.author

Sanchez, Ana M

dc.contributor.author

Denny, Thomas N

dc.contributor.author

Ferrari, Guido

dc.coverage.spatial

Netherlands

dc.date.accessioned

2016-06-01T14:46:38Z

dc.date.issued

2016-06

dc.description.abstract

Assays that assess cellular mediated immune responses performed under Good Clinical Laboratory Practice (GCLP) guidelines are required to provide specific and reproducible results. Defined validation procedures are required to establish the Standard Operating Procedure (SOP), include pass and fail criteria, as well as implement positivity criteria. However, little to no guidance is provided on how to perform longitudinal assessment of the key reagents utilized in the assay. Through the External Quality Assurance Program Oversight Laboratory (EQAPOL), an Interferon-gamma (IFN-γ) Enzyme-linked immunosorbent spot (ELISpot) assay proficiency testing program is administered. A limit of acceptable within site variability was estimated after six rounds of proficiency testing (PT). Previously, a PT send-out specific within site variability limit was calculated based on the dispersion (variance/mean) of the nine replicate wells of data. Now an overall 'dispersion limit' for the ELISpot PT program within site variability has been calculated as a dispersion of 3.3. The utility of this metric was assessed using a control sample to calculate the within (precision) and between (accuracy) experiment variability to determine if the dispersion limit could be applied to bridging studies (studies that assess lot-to-lot variations of key reagents) for comparing the accuracy of results with new lots to results with old lots. Finally, simulations were conducted to explore how this dispersion limit could provide guidance in the number of replicate wells needed for within and between experiment variability and the appropriate donor reactivity (number of antigen-specific cells) to be used for the evaluation of new reagents. Our bridging study simulations indicate using a minimum of six replicate wells of a control donor sample with reactivity of at least 150 spot forming cells per well is optimal. To determine significant lot-to-lot variations use the 3.3 dispersion limit for between and within experiment variability.

dc.identifier

http://www.ncbi.nlm.nih.gov/pubmed/27021273

dc.identifier

S0022-1759(16)30053-9

dc.identifier.eissn

1872-7905

dc.identifier.uri

https://hdl.handle.net/10161/12062

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

J Immunol Methods

dc.relation.isversionof

10.1016/j.jim.2016.03.004

dc.subject

Bridging study

dc.subject

ELISpot

dc.subject

EQAPOL

dc.subject

Poisson

dc.subject

Proficiency testing

dc.subject

Variability

dc.title

Variability of the IFN-γ ELISpot assay in the context of proficiency testing and bridging studies.

dc.type

Journal article

duke.contributor.orcid

Ferrari, Guido|0000-0001-7747-3349

pubs.author-url

http://www.ncbi.nlm.nih.gov/pubmed/27021273

pubs.begin-page

69

pubs.end-page

76

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Duke Human Vaccine Institute

pubs.organisational-group

Global Health Institute

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Duke Human Vaccine Institute

pubs.organisational-group

Molecular Genetics and Microbiology

pubs.organisational-group

School of Medicine

pubs.organisational-group

Staff

pubs.organisational-group

Surgery

pubs.organisational-group

Surgery, Surgical Sciences

pubs.organisational-group

University Institutes and Centers

pubs.publication-status

Published

pubs.volume

433

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMID27021273 _PubMed in process.pdf
Size:
742.58 KB
Format:
Adobe Portable Document Format
Description:
Accepted version